» Articles » PMID: 37113607

The Influence of Immortal Time Bias in Observational Studies Examining Associations of Antifibrotic Therapy with Survival in Idiopathic Pulmonary Fibrosis: A Simulation Study

Overview
Specialty General Medicine
Date 2023 Apr 28
PMID 37113607
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Immortal time bias (ITB) has been overlooked in idiopathic pulmonary fibrosis (IPF). We aimed to identify the presence of ITB in observational studies examining associations between antifibrotic therapy and survival in patients with IPF and illustrate how ITB may affect effect size estimates of those associations.

Methods: Immortal time bias was identified in observational studies using the ITB Study Assessment Checklist. We used a simulation study to illustrate how ITB may affect effect size estimates of antifibrotic therapy on survival in patients with IPF based on four statistical techniques including time-fixed, exclusion, time-dependent and landmark methods.

Results: Of the 16 included IPF studies, ITB was detected in 14 studies, while there were insufficient data for assessment in two others. Our simulation study showed that use of time-fixed [hazard ratio (HR) 0.55, 95% confidence interval (CI) 0.47-0.64] and exclusion methods (HR 0.79, 95% CI 0.67-0.92) overestimated the effectiveness of antifibrotic therapy on survival in simulated subjects with IPF, in comparison of the time-dependent method (HR 0.93, 95% CI 0.79-1.09). The influence of ITB was mitigated using the 1 year landmark method (HR 0.69, 95% CI 0.58-0.81), compared to the time-fixed method.

Conclusion: The effectiveness of antifibrotic therapy on survival in IPF can be overestimated in observational studies, if ITB is mishandled. This study adds to the evidence for addressing the influence of ITB in IPF and provides several recommendations to minimize ITB. Identifying the presence of ITB should be routinely considered in future IPF studies, with the time-dependent method being an optimal approach to minimize ITB.

Citing Articles

Antifibrotics and mortality in idiopathic pulmonary fibrosis: external validity and avoidance of immortal time bias.

Hozumi H, Miyashita K, Nakatani E, Inoue Y, Yasui H, Suzuki Y Respir Res. 2024; 25(1):293.

PMID: 39085869 PMC: 11293013. DOI: 10.1186/s12931-024-02922-y.


Effect of Antifibrotic Use on Mortality in Patients with Idiopathic Pulmonary Fibrosis.

Xu H, Hui S, Lee J, Zhang Z, Boente R Ann Am Thorac Soc. 2024; 21(10):1407-1415.

PMID: 39012168 PMC: 11451888. DOI: 10.1513/AnnalsATS.202312-1054OC.


Methodological biases in observational hospital studies of COVID-19 treatment effectiveness: pitfalls and potential.

Martinuka O, Hazard D, Marateb H, Mansourian M, Mananas M, Romero S Front Med (Lausanne). 2024; 11:1362192.

PMID: 38576716 PMC: 10991758. DOI: 10.3389/fmed.2024.1362192.

References
1.
Mansournia M, Nazemipour M, Etminan M . Causal diagrams for immortal time bias. Int J Epidemiol. 2021; 50(5):1405-1409. DOI: 10.1093/ije/dyab157. View

2.
Suissa S . Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2007; 167(4):492-9. DOI: 10.1093/aje/kwm324. View

3.
Nathan S, Brown A, Mogulkoc N, Soares F, Collins A, Cheng J . The association between white blood cell count and outcomes in patients with idiopathic pulmonary fibrosis. Respir Med. 2020; 170:106068. DOI: 10.1016/j.rmed.2020.106068. View

4.
Larson D, Crowson C, Devick K, Lewallen D, Berry D, Kremers H . Immortal Time Bias in the Analysis of Time-to-Event Data in Orthopedics. J Arthroplasty. 2021; 36(10):3372-3377. PMC: 8478821. DOI: 10.1016/j.arth.2021.06.012. View

5.
Abrahami D, Hudson M, Suissa S . Statins and lower mortality in rheumatic diseases: An effect of immortal time bias?. Semin Arthritis Rheum. 2021; 51(1):211-218. DOI: 10.1016/j.semarthrit.2020.11.010. View